Literature DB >> 11698061

Sex differences in antinociceptive and motoric effects of cannabinoids.

A H Tseng1, R M Craft.   

Abstract

Cannabinoids are currently used for the treatment of excessive weight loss and nausea; however, there are very few studies that have examined cannabinoid effects in females of any species. A previous study has shown that there are sex differences in cannabinoid pharmacokinetics in rats, suggesting that there could be sex differences in cannabinoid-induced behaviors. To address this issue, Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol (natural cannabinoids) or (-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)-phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol) (CP55940, a synthetic cannabinoid) was administered i.p. to male and female Sprague-Dawley rats, who were tested on the 50 degrees C warm water tail withdrawal, paw pressure, catalepsy bar and spontaneous locomotor activity tests at various times post-injection. At the doses tested, all three cannabinoid agonists produced greater effects in females than males in two or more behavioral tests. This study demonstrates that there are sex differences in the behavioral effects of cannabinoids in the rat.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698061     DOI: 10.1016/s0014-2999(01)01267-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  66 in total

Review 1.  Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system?

Authors:  Rebecca M Craft; Julie A Marusich; Jenny L Wiley
Journal:  Life Sci       Date:  2012-06-20       Impact factor: 5.037

2.  Receptor subtypes and signal transduction mechanisms contributing to the estrogenic attenuation of cannabinoid-induced changes in energy homeostasis.

Authors:  Neal Washburn; Amanda Borgquist; Kate Wang; Garrett S Jeffery; Martin J Kelly; Edward J Wagner
Journal:  Neuroendocrinology       Date:  2012-08-28       Impact factor: 4.914

3.  Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed-dose ratio.

Authors:  David R Maguire; Charles P France
Journal:  Eur J Pharmacol       Date:  2017-11-26       Impact factor: 4.432

4.  Orbitofrontal and caudate volumes in cannabis users: a multi-site mega-analysis comparing dependent versus non-dependent users.

Authors:  Yann Chye; Nadia Solowij; Chao Suo; Albert Batalla; Janna Cousijn; Anna E Goudriaan; Rocio Martin-Santos; Sarah Whittle; Valentina Lorenzetti; Murat Yücel
Journal:  Psychopharmacology (Berl)       Date:  2017-04-01       Impact factor: 4.530

5.  Cannabidiol-Δ9-tetrahydrocannabinol interactions on acute pain and locomotor activity.

Authors:  Stevie C Britch; Jenny L Wiley; Zhihao Yu; Brian H Clowers; Rebecca M Craft
Journal:  Drug Alcohol Depend       Date:  2017-04-15       Impact factor: 4.492

6.  Cannabidiol modulation of antinociceptive tolerance to Δ9-tetrahydrocannabinol.

Authors:  Nicholas Z Greene; Jenny L Wiley; Zhihao Yu; Brian H Clowers; Rebecca M Craft
Journal:  Psychopharmacology (Berl)       Date:  2018-09-20       Impact factor: 4.530

7.  Evaluation of sex differences in cannabinoid dependence.

Authors:  Julie A Marusich; Timothy W Lefever; Kateland R Antonazzo; Rebecca M Craft; Jenny L Wiley
Journal:  Drug Alcohol Depend       Date:  2014-02-12       Impact factor: 4.492

8.  Sex-dependent effects of cannabis-induced analgesia.

Authors:  Ziva D Cooper; Margaret Haney
Journal:  Drug Alcohol Depend       Date:  2016-08-05       Impact factor: 4.492

9.  Effects of Δ9-THC and cannabidiol vapor inhalation in male and female rats.

Authors:  Mehrak Javadi-Paydar; Jacques D Nguyen; Tony M Kerr; Yanabel Grant; Sophia A Vandewater; Maury Cole; Michael A Taffe
Journal:  Psychopharmacology (Berl)       Date:  2018-06-16       Impact factor: 4.530

10.  Anti-migraine effect of ∆9-tetrahydrocannabinol in the female rat.

Authors:  Ram Kandasamy; Cole T Dawson; Rebecca M Craft; Michael M Morgan
Journal:  Eur J Pharmacol       Date:  2017-10-28       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.